Posledná aktualizácia :
28/04/2024
Výskumné tímy - Clinical Pharmacy Department, University Hospital Necker-Enfants Malades   PDF  
Francúzsko
Nemocnica
Clinical Pharmacy Department, University Hospital Necker-Enfants Malades
Paris
Odkazy na literatúru   Odkazy na literatúru   (11)  
1
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. (salvatore.cisternino@aphp.fr)
Pharmaceutics - 2023 - ,15, 957.
2
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. (philippe-henri.secretan@u-psud.fr)
Molecules - 2022 - ; 27(3): 1070.
3
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
The Scientific World Journal - 2022 -
4
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
Pharm Dev Technol - 2021 -
5
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
EJHP - 2021 -
6
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. ()
Am J Hosp Pharm - 2021 - ;78,9:825–831
7
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier (joel.schlatter@aphp.fr)
Int J Antimicrob Agents - 2020 - ; 56: 106083.
8
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. (joel.schlatter@ aphp.fr)
EJHP - 2018 - ; 25, e2
9
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. ()
Int J Pharm Compound - 2015 - ; 19, 1: 73-77.
10
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. ()
Int J Pharm Compound - 2014 - ; 18, 5: 427-431.
11
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R (philippe.bourget@nck.aphp.fr)
Antimicrob Agents Chemother - 2014 - ; 58 : 2849-2855.

Zoznam zlúčenín   Skúmané zlúčeniny   (11)  
Imunosupresívum Perorálny roztok Azathioprine
Antibiotikum Injekcia Ceftazidime
Protinádorová liečba Dermálny prípravok Erlotinib
Antiflogistikum Perorálny roztok Hydrocortisone
Antiflogistikum Perorálny roztok Hydroxychloroquine sulfate
Celkové anestetikum Perorálny roztok Ketamine hydrochloride
Rôzne Perorálny roztok L-Methionine
Protinádorová liečba Injekcia Pemetrexed diarginine
Protinádorová liečba Perorálny roztok Ruxolitinib
Antimykotikum Dermálny prípravok Voriconazole
Antikoagulans Perorálny roztok Warfarin sodium

  Mentions Légales